Cargando…
Randomized phase II trial of MRI-guided salvage radiotherapy for prostate cancer in 4 weeks versus 2 weeks (SHORTER)
BACKGROUND: Ultra-hypofractionated image-guided stereotactic body radiotherapy (SBRT) is increasingly used for definitive treatment of localized prostate cancer. Magnetic resonance imaging-guided radiotherapy (MRgRT) facilitates improved visualization, real-time tracking of targets and/or organs-at-...
Autores principales: | Marciscano, Ariel E., Wolfe, Sydney, Zhou, Xi Kathy, Barbieri, Christopher E., Formenti, Silvia C., Hu, Jim C., Molina, Ana M., Nanus, David M., Nauseef, Jones T., Scherr, Douglas S., Sternberg, Cora N., Tagawa, Scott T., Nagar, Himanshu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10463903/ https://www.ncbi.nlm.nih.gov/pubmed/37608258 http://dx.doi.org/10.1186/s12885-023-11278-3 |
Ejemplares similares
-
A randomized phase II trial of MR-guided prostate stereotactic body radiotherapy administered in 5 or 2 fractions for localized prostate cancer (FORT)
por: Wolfe, Sydney, et al.
Publicado: (2023) -
Differential Use of Radiotherapy Fractionation Regimens in Prostate Cancer
por: Qureshy, Sarah A., et al.
Publicado: (2023) -
Cancer and COVID-19 — potentially deleterious effects of delaying radiotherapy
por: Nagar, Himanshu, et al.
Publicado: (2020) -
Complex implementation factors demonstrated when evaluating cost-effectiveness and monitoring racial disparities associated with [(18)F]DCFPyL PET/CT in prostate cancer men
por: Subramanian, Kritika, et al.
Publicado: (2023) -
Trends in Diagnosis and Disparities in Initial Management of High-Risk Prostate Cancer in the US
por: Agrawal, Vishesh, et al.
Publicado: (2020)